SAN DIEGO — In patients with chronic rheumatic inflammatory disease, those who continue TNF inhibition during pregnancy have similar obstetrical outcomes as those who cease treatment, according to data presented at ACR Convergence 2023.
Moreover, pregnant patients who maintained their use of TNF inhibitors experienced fewer severe maternal infections vs. those who stopped, the researchers wrote.
“As you may know, patients with rheumatic diseases such as lupus, rheumatoid arthritis and spondyloarthritis tend to present with worse pregnancy outcomes, compared with the general population,”
